Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Oct. 26, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories. Shareholders who purchased shares of ABT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Abbott Laboratories (NYSE: ABT) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.Lead Plaintiff Deadline: October 31, 2022 No obligation or cost to you.

ABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Shareholders

Citigroup

Dover

Procter & Gamble

Pool

Tractor Supply

Tesla

Whirlpool

One thing's clear at the start of the corporate earnings season: Inflation is still a hot topic for companies.

Inflation is dominating the conversation on earnings calls. Here's what execs are saying

NEW YORK , Oct. 23, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline. SO WHAT: If you purchased Abbott securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ABT APPROACHING DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses Over $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT

NEW ORLEANS , Oct. 21, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

New York, New York--(Newsfile Corp. - October 21, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"), of the important October 31, 2022 lead plaintiff deadline.

ABT FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors With Losses Over $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT

Coca-Cola

Target

These companies have what it takes to offer earnings growth over time.

Want Passive Income? 3 Dividend Kings to Buy Right Now

New York, New York--(Newsfile Corp. - October 20, 2022) - Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.The lawsuit on behalf of Abbott investors has been commenced in the the United States District Court for the Northern District of Illinois.

Abbott Class Action: Levi & Korsinsky Reminds Abbott Laboratories Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 31, 2022 - ABT

Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)

CEDARHURST, N.Y. , Oct. 19, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period").

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT

U.S. Housing Starts Declined in September

Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up

Abbott Laboratories CEO Robert Ford says the company replaced leadership at its troubled Michigan facility and is building a new infant formula plant.

Abbott CEO provides update on progress as baby formula shortage persists

SoFi Technologies

Alphabet

The stock market remains near 52-week lows, and it might be the time to start looking for stocks to buy at a discount. Following September's inflation figures, things don't appear to change soon.

3 Stocks Set to Soar From 52-Week Lows

The company, which had halted production at the Sturgis, Mich., plant earlier in the year, also said it will spend $500 million to build a new formula plant.

Abbott Names New Leadership at Troubled Baby-Formula Plant

Is the billion-dollar COVID-19 testing sales boom over?

Abbott Laboratories predicts COVID-19 will be endemic this winter

A potential drop-off in COVID-19 testing sales is weighing on the healthcare giant's shares today.

Why Abbott Laboratories Stock Is Slumping Today

While Abbott Laboratories beat analysts' expectations due to demand for Covid-19 at-home tests, a decline by its medical-device business and broader headwinds helped send its shares down.

Rapid Covid Tests Can't Keep Abbott Healthy Forever

Abbott Laboratories (NYSE:ABT ) Q3 2022 Earnings Conference Call October 19, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing and Acquisition Robert Ford - Chairman and CEO Bob Funck - Executive Vice President, Finance and CFO Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Josh Jennings - Cowen Vijay Kumar - Evercore ISI Travis Steed - Bank of America Operator Good morning and thank you for standing by. Welcome to Abbott's Third Quarter 2022 Earnings Conference Call.

Abbott Laboratories (ABT) Q3 2022 Earnings Call Transcript

Abbott Laboratories reported better-than-expected third-quarter declines and raised its earnings guidance. But ABT stock tumbled.

Abbott Labs Reports Narrower-Than-Expected Quarterly Declines, And Shares Topple

Abbott says sales of medical devices rose more than 11% in the third quarter.

Abbott Raises Guidance but Says Quarterly Sales Hit by Baby Formula Shortage

Abbott Laboratories ABT, +1.41% said Wednesday that it had earnings of $1.4 billion, or $1.15 per share, in the third quarter of 2022, compared with $2.1 billion, or $1.40, in the same quarter a year ago. Adjusted earnings per share were $1.15, against a FactSet consensus of 94 cents.

Abbott attributes Q3 sales decline to baby formula shortage, less COVID-19 testing

Abbott Laboratories on Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and pharmaceutical products.

Abbott raises 2022 profit forecast for second time

Worldwide  sales of $10.4 billion in the third quarter Raises full-year earnings-per-share guidance Continues to strengthen portfolio with new product approvals and launches ABBOTT PARK, Ill., Oct. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance

NEW YORK , Oct. 17, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) ***Please contact fmoore@moorekuehn.com   Abbott is a medical device and health care company that provides a broad line of products, including various forms of infant formula. By early 2022, Abbott was responsible for producing 40 percent of the United States' infant formula.

News for Abbott Labs Stock (ABT)